Lipoprotein Profile, Lipoprotein-associated Phospholipase A2 and Cardiovascular Risk in Hemodialysis Patients

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2015 May 15

PMID 25971848

Citations 3

Authors

Roberta Rolla

Andreana De Mauri

Ambra Valsesia

Matteo Vidali

Doriana Chiarinotti

Giorgio Bellomo

Affiliations

Soon will be listed here.

Abstract

Background: Cardiovascular disease is the leading cause of morbidity and mortality in hemodialysis patients; the increased risk of cardiovascular disease is due to accelerated atherosclerosis, inflammation and impaired lipoprotein metabolism. We aimed to evaluate lipoprotein-associated phospholipase A2 (Lp-PLA2) and some pro-inflammatory aspects of the lipoprotein profile in dialyzed patients in order to evaluate the relationship with the accelerated atherosclerosis and vascular accidents.

Methods: In 102 dialysis patients and 40 non-uremic controls, we investigated the lipoprotein plasma profile, high sensitivity C-reactive protein (CRP), ceruloplasmin and serum amyloid A protein (SAA), and followed patients for 1 year to analyze the risk of acute cardiovascular events.

Results: Total cholesterol, low-density lipoprotein and high-density lipoprotein plasma levels were significantly lower in uremic patients than controls, whereas CRP, SAA, ceruloplasmin, Lp-PLA2 and their ratio with apolipoprotein A1 were significantly higher. Patients with Lp-PLA2 levels >194 nmol/min/ml had more acute cardiovascular events than patients with lower values.

Conclusion: Our results show that in dialysis subjects: (1) low-density lipoproteins show a more atherogenic phenotype than in the general population; (2) high-density lipoproteins are less anti-inflammatory; (3) Lp-PLA2 could potentially be used to evaluate cardiovascular risk.

Citing Articles

Compliance, Adherence and Concordance Differently Predict the Improvement of Uremic and Microbial Toxins in Chronic Kidney Disease on Low Protein Diet.

Andreana De Mauri , Carrera D, Vidali M, Bagnati M, Rolla R, Riso S Nutrients. 2022; 14(3).

PMID: 35276846 PMC: 8839589. DOI: 10.3390/nu14030487.

New insights into the emerging effects of inflammatory response on HDL particles structure and function.

Su X, Zhang G, Cheng Y, Wang B Mol Biol Rep. 2021; 48(7):5723-5733.

PMID: 34319542 DOI: 10.1007/s11033-021-06553-0.

Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients.

Andreana De Mauri , Vidali M, Chiarinotti D, Bellomo G, Rolla R J Nephrol. 2018; 32(2):283-288.

PMID: 30168082 DOI: 10.1007/s40620-018-0521-3.

References

Vaziri N, Bai Y, Yuan J, Said H, Sigala W, Ni Z . ApoA-1 mimetic peptide reverses uremia-induced upregulation of pro-atherogenic pathways in the aorta. Am J Nephrol. 2010; 32(3):201-211. DOI: 10.1159/000316479. View

Libby P, Ridker P, Hansson G . Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54(23):2129-38. PMC: 2834169. DOI: 10.1016/j.jacc.2009.09.009. View

Stenvinkel P . Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010; 268(5):456-67. DOI: 10.1111/j.1365-2796.2010.02269.x. View

Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C . Uremia alters HDL composition and function. J Am Soc Nephrol. 2011; 22(9):1631-41. PMC: 3171935. DOI: 10.1681/ASN.2010111144. View

Kushiya F, Wada H, Sakakura M, Mori Y, Gabazza E, Nishikawa M . Effects of lipid abnormalities on arteriosclerosis and hemostatic markers in patients under hemodialysis. Clin Appl Thromb Hemost. 2003; 9(3):203-10. DOI: 10.1177/107602960300900304. View

Rizzo M, Pernice V, Frasheri A, Di Lorenzo G, Rini G, Spinas G . Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol (Oxf). 2008; 70(6):870-5. DOI: 10.1111/j.1365-2265.2008.03407.x. View

Beattie J, Soman S, Sandberg K, Yee J, Borzak S, Garg M . Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis. 2001; 37(6):1191-200. DOI: 10.1053/ajkd.2001.24522. View

Kalantar-Zadeh K, Kopple J, Kamranpour N, Fogelman A, Navab M . HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 2007; 72(9):1149-56. DOI: 10.1038/sj.ki.5002491. View

Chisolm G, Steinberg D . The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med. 2000; 28(12):1815-26. DOI: 10.1016/s0891-5849(00)00344-0. View

10.

Osorio A, Ortega E, De Haro T, Torres J, Sanchez P, Ruiz-Requena E . Lipid profiles and oxidative stress parameters in male and female hemodialysis patients. Mol Cell Biochem. 2011; 353(1-2):59-63. DOI: 10.1007/s11010-011-0774-9. View

11.

Pedersen T, Bro S, Andersen M, Etzerodt M, Jauhiainen M, Moestrup S . Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient mice. Atherosclerosis. 2008; 202(2):372-81. DOI: 10.1016/j.atherosclerosis.2008.04.041. View

12.

Zalewski A, Macphee C . Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005; 25(5):923-31. DOI: 10.1161/01.ATV.0000160551.21962.a7. View

13.

Pencak P, Czerwienska B, Ficek R, Wyskida K, Kujawa-Szewieczek A, Olszanecka-Glinianowicz M . Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients. BMC Nephrol. 2013; 14:10. PMC: 3556324. DOI: 10.1186/1471-2369-14-10. View

14.

Barter P, Nicholls S, Rye K, Anantharamaiah G, Navab M, Fogelman A . Antiinflammatory properties of HDL. Circ Res. 2004; 95(8):764-72. DOI: 10.1161/01.RES.0000146094.59640.13. View

15.

Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N . Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005; 20(6):1048-56. DOI: 10.1093/ndt/gfh813. View

16.

McGillicuddy F, de la Llera Moya M, Hinkle C, Joshi M, Chiquoine E, Billheimer J . Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009; 119(8):1135-45. PMC: 4937877. DOI: 10.1161/CIRCULATIONAHA.108.810721. View

17.

Stenvinkel P, Carrero J, Axelsson J, Lindholm B, Heimburger O, Massy Z . Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol. 2008; 3(2):505-21. PMC: 6631093. DOI: 10.2215/CJN.03670807. View

18.

Caslake M, Packard C, Suckling K, Holmes S, Chamberlain P, Macphee C . Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000; 150(2):413-9. DOI: 10.1016/s0021-9150(99)00406-2. View

19.

Navab M, Reddy S, Van Lenten B, Fogelman A . HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011; 8(4):222-32. DOI: 10.1038/nrcardio.2010.222. View

20.

Jang E, Park Y, Hur J, Kim M, Ko S, Baek K . Higher levels of small dense low-density lipoprotein (LDL) are associated with cardiac autonomic neuropathy in patients with type 2 diabetes. Diabet Med. 2013; 30(6):694-701. DOI: 10.1111/dme.12176. View